Letters
Avastin versus Lucentis
The scientific community should lobby to be able to apply for drug licences
BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3553 (Published 22 May 2012) Cite this as: BMJ 2012;344:e3553- Silvio Garattini, director1,
- Vittorio Bertele’, head, drug regulatory policies laboratory1
- 1Mario Negri Institute for Pharmacological Research, via Giuseppe La Masa 19, 20156 Milan, Italy
- silvio.garattini{at}marionegri.it
Torjesen and Campbell and colleagues recently stoked the Avastin-Lucentis embers.1 2 3 4 This is a classic case of industry not only having no interest in applying for a new indication but also having a specific interest in not doing so. It is disappointing that public …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.